Neutralizing antibodies (NAbs), and their concentration in sera of convalescents and vaccinees are a solid correlate of protection from COVID-19. The antibody concentrations in clinical samples that neutralize SARS-CoV-2 are difficult and very cumbersome to assess with conventional virus neutralization tests (cVNTs), which require work with the infectious virus and biosafety level 3 containment precautions. Alternative virus neutralization tests currently in use are mostly surrogate tests based on direct or competitive ELISA formats or use viral vectors with the spike protein as the single structural component of SARS-CoV-2. To overcome these obstacles, we developed a virus-free, safe and very fast (4.5 h) in vitro diagnostic test based on engineered yet authentic SARS-CoV-2 virus-like-particles (VLPs). They share all features of the original SARS-CoV-2 but lack the viral RNA genome and thus are non-infectious. NAbs induced by infection or vaccination, but also potentially neutralizing monoclonal antibodies can be reliably quantified and assessed with ease and within hours with our test, because they interfere and block the ACE2-mediated uptake of VLPs by recipient cells. Results from the VLP neutralization test (VLPNT) show excellent correlation to a cVNT with fully infectious SARS-CoV-2 and allow to estimate the reduced neutralization capacity of COVID-19 vaccinee sera with variants of concern of SARS-CoV-2.
Emerging SARS-CoV-2 variants of concern/interest (VOC/VOI) raise questions about effectiveness of neutralizing antibodies derived from infection or vaccination. Here, we have assessed a total of 104 blood specimens, consisting of convalescent samples after infection with early-pandemic SARS-CoV-2 (pre-VOC) or with Alpha, Beta, Gamma or Delta, post- vaccination samples after double-dose mRNA-vaccination as well as samples after vaccine break-through infections with Delta or Omicron. Neutralization against seven authentic SARS-CoV-2 isolates (B.1, Alpha, Beta, Gamma, Delta, Zeta, Omicron) was assessed by plaque-reduction neutralization assay. We found highest neutralization titers against the homologous (previously infecting) variant, with lower neutralization efficiency against heterologous variants. Loss of neutralization against heterologous variants showed considerably variability between convalescent groups suggesting that a variant-specific infection background influences immune escape characteristics. Convalescent samples from pre-VOC SARS-CoV-2, Alpha, Beta, Gamma and Delta-infected individuals all showed a significant loss of neutralization for Omicron but to a varying degree (23.0-fold in Beta-convalescent up to 56.1-fold in Alpha-convalescent samples), suggesting that infection-derived immunity, independent of the infecting variant is most likely only poorly protective against Omicron. Of note, former variant of concern Zeta showed also a pronounced escape form neutralization of up to 28.2-fold in Alpha convalescent samples. Two-dose vaccinated individuals showed robust neutralization against B.1 and only slightly lower neutralization titers for Alpha, Beta, Gamma, Delta and Zeta, with fold-change reduction for heterologous virus between 2.8 (for Alpha) to 6.9 (for Beta). In contrast to convalescent specimens, escape from neutralization for Zeta was largely restored in vaccinated individuals, while Omicron showed a strongly reduced neutralization of 85.7-fold compared to pre-VOC SARS-CoV-2. Robust neutralization titers were observed in double- vaccinated individuals with subsequent Delta break-through infections, that also neutralized Omicron with a loss of only 12.5-fold. Individuals with an Omicron breakthrough infection showed high neutralization titers for both Delta and Omicron, with only a 1.5-fold loss for Delta neutralization. This suggests that infection with antigenically different variants can boost immunity against variants that are antigenically similar to the vaccine strain. We conclude that for the assessment of escape from neutralization by new VOCs such as Omicron, the complexity of background immunity due to individual and regional differences needs to be taken into account. Geographic variation in the proportion of individual with infection- or vaccination-derived immunity or a combination of both could have substantial influence on the course of the pandemic. Combined infection/vaccination immunity after break-through infections could ultimately lead to broad immunity also against non-homologous variants.
Background To prevent nosocomial transmission of SARS-CoV-2, infection control measures are implemented for patients with symptoms compatible with COVID-19 until reliable test results are available. This delay targeted admission to the most appropriate ward based on the medical condition. SARS-CoV-2 rapid antigen detection (RAD) tests and point of care (POC) rapid RT-PCR were introduced at emergency departments (EDs) in late 2020, but the consequence on targeted admission is unknown. Objectives To assess the effect of RAD tests and POC rapid RT-PCR (VitaPCR, Credo Diagnostics, Singapore) on targeted admission. Methods Patients presenting at the ED of a referral hospital (N = 2,940) between 13-Nov-2020 and 12-Jan-2021 were included. The study period was delimited by introduction of RAD tests and VitaPCR. Participant data was collected retrospectively, and outcome variables were length-of-stay (LoS), intrahospital transfers and targeted admission to COVID-19 ward. Results RAD tests reduced ED LoS for participants with positive tests or that were not tested. Negative VitaPCR results reduced mean hospital LoS by 1.5 (95%CI: 0.3-2.7) days and admissions to COVID –19 wards from 34.5 (95%CI: 28.9-40.5) to 14.7 (95%CI: 11.1-19.1) per 100 admissions. Introduction of VitaPCR reduced transfers between hospital wards in the first 5 days from 50.0 (95%CI: 45.0-55.0) to 34.0 (95%CI: 30.3-37.9) per 100 admissions. Conclusion RAD tests enabled rapid detection of SARS-CoV-2 infection which had pronounced effects on LoS at the ED. VitaPCR added the possibility of exclusion of the infection which increased targeted admissions, reduced intrahospital transfers and lead to shorter stay at the hospital.
This study aims to explore and understand the common belief that COVID infection rate is highly dependent on either the outside temperature and/or the humidity. Thirty six regions/states from two humid-tropical countries, namely Brazil and Colombia and two countries with temperate climate, France and Italy, are studied over the period of October to December. Daily outside temperature, relative humidity and hospitalization/cases are analyzed using Spearman9s correlation. The eighteen cold regions of France and Italy has seen an average drop in temperature from 10C to 6C and 17C to 7C, respectively, and France recorded an addition of 2.3 million cases, while Italy recorded an addition of 1.8 million cases. Outside temperature did not fluctuate much in tropical countries, but Brazil and Colombia added 4.17 million and 1.1 million cases, respectively. Koppen Geiger classification showed the differences in weather pattern between the four countries, and the analysis showed that there is very weak correlation between either outside weather and/or relative humidity alone to the COVID-19 pandemic.
Introduction: From July through October of 2021, several countries issued recommendations for increased COVID-19 vaccine protection for individuals with one or more immunocompromised (IC) conditions. It is critically important to understand the vaccine effectiveness (VE) of COVID-19 vaccines among IC populations as recommendations are updated over time in response to the evolving COVID-19 pandemic. Areas covered: A targeted literature review was conducted to identify real-world studies that assessed COVID-19 VE in IC populations between December 2020 and September 2021. A total of 10 studies from four countries were identified and summarized in this review. Expert opinion/commentary: VE of the widely available COVID-19 vaccines, including BNT162b2 (Pfizer/BioNTech), mRNA-1273 (Moderna), Ad26.COV2.S (Janssen), and ChAdOx1 nCoV-19 (Oxford/AstraZeneca), ranged from 64%-90% against SARS-CoV-2 infection, 73%-84% against symptomatic illness, 70%-100% against severe illness, and 63%-100% against COVID-19-related hospitalization among the fully vaccinated IC populations included in the studies. COVID-19 VE for most outcomes in the IC populations included in these studies was lower than in the general populations. These findings provide preliminary evidence that the IC population requires greater protective measures to prevent COVID-19 infection and associated illness, hence should be prioritized while implementing recommendations of additional COVID-19 vaccine doses.
The research of rare and devastating orphan diseases such as Idiopathic Pulmonary Fibrosis (IPF) has been limited by the rarity of the disease itself. The prognosis is poor - the prevalence of IPF is only ~4-times the incidence of the condition, limiting the recruitment of patients to trials and studies of the underlying biology of the disease. However, global biobanking efforts can dramatically alter the future of IPF research. Here we describe the largest meta-analysis of IPF, with 8,492 patients and 1,355,819 population controls from 13 biobanks around the globe. Finally, we combine the meta-analysis with the largest available meta-analysis of IPF so far, reaching 11,160 patients and 1,364,410 population controls in analysis. We identify seven novel genome-wide significant loci, only one of which would have been identified if the analysis had been limited to European ancestry individuals. We observe notable pleiotropy across IPF susceptibility and severe COVID-19 infection, beyond what is known to date. We also note a significant unexplained sex-heterogeneity effect at the strongest IPF locus MUC5B.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus disease 2019 (COVID-19) with respiratory distress and systemic hyperinflammation. The primary objective of this single-blind randomized controlled proof-of-concept clinical trial was to establish the effects of intravenous (i.v.) omega-3 (n-3) polyunstaurated fatty acid (PUFA) treatment compared to placebo on inflammatory markers in COVID-19, represented by leukocytes as well as inflammatory protein and lipid mediators. Here we also present an exploratory analysis of the mechanisms of action to elucidate the potential to resolve the COVID-19 hyperinflammation through interfering with lipid mediators. Inclusion criteria were COVID-19 diagnosis and clinical status requiring hospitalization. After randomized 1:1 to a once daily i.v. infusion (2 mL/kg) of either placebo (NaCl) or n-3 PUFA emulsion containing 10g of fish oil per 100 mL, results from 22 older subjects (mean age 81+/-6.1 years) were analyzed. The neutrophil to lymphocyte ratio was significantly decreased after n-3 PUFA administration. Changes in the PUFA metabolome assessed by LC-MS/MS-based lipid metabolite analysis established increased proresolving lipid mediator precursor levels and decreased formation of leukotoxin and isoleukotoxin diols by n-3 PUFA treatment. The mechanistic exploration revealed decreased immunothrombosis and preserved interferon-response. Finally, n-3 PUFA treatment may serve to limit cortisone-induced immunosuppression, including preserving leukocyte phagocytic capacity. In conclusion, i.v. n-3 PUFA administration was safe and feasible during hospitalization of multimorbid older subjects for COVID-19. The results identified a n-3 PUFA treatment mediated lipid signature of increased proresolving precursor levels and decreased leukotoxin diols in parallel to beneficial immune responses. EudraCT: 2020-002293-28; clinicaltrials.gov: NCT04647604.
Since February 2021, health care workers in Japan have been preferentially vaccinated with a messenger RNA vaccine (BNT162b2/Pfizer) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). While many studies have confirmed that this vaccine is highly effective in reducing hospitalizations and deaths from coronavirus disease 2019 (COVID-19), antibody titers tend to decline at 3 months, leading to a risk of breakthrough infections. Thus, information is needed to support decision making regarding the third vaccination. In this study, we investigated transition of the anti-SARS-CoV-2 receptor-binding domain (RBD) IgG and neutralizing antibody titers of 41 vaccinated Japanese healthcare workers. Samples were collected seven times starting 1 week before vaccination until 6 months post-vaccination. Anti- SARS-CoV-2 RBD IgG levels peaked at 7 days after the booster, then declined over time and decreased to <10% at 6 months after the booster. Workers with low anti-SARS-CoV-2 RBD IgG levels also had low neutralizing antibody titers. These data support the active use of boosters for healthcare workers, especially for those with low anti-SARS-CoV-2 RBD IgG levels.
Immunization against SARS-CoV-2, the causative agent of coronavirus disease-19 (COVID-19) occurs via natural infection or vaccination. However, it is currently unknown how long infection- or vaccination-induced immunological memory will last. We performed a longitudinal evaluation of immunological memory to SARS-CoV-2 following mRNA vaccination in naive and COVID-19 recovered individuals. We found that cellular immunity is still detectable 8 months after vaccination, while antibody levels decline significantly especially in naive subjects. We also found that a booster injection is more efficacious in reactivating immunological memory to spike protein in naive than in previously SARS-CoV-2 infected subjects. Finally, we observed a similar kinetics of decay of humoral and cellular immunity to SARS- CoV-2 up to one year following natural infection in a cohort of unvaccinated individuals. Short-term persistence of humoral immunity may account for reinfections and breakthrough infections, although long-lived memory B and CD4+ T cells may protect from severe disease. A booster dose restores optimal anti-spike immunity in naive subjects, while the need for vaccinated COVID-19 recovered subjects has yet to be defined.
There are concerns that the SARS-CoV-2 Omicron variant evades immune responses due to unusually high numbers of mutations on the spike protein. Here we report a super-spreading event of Omicron infections amongst triple-vaccinated healthcare workers, infecting 21 of 33 attending a private gathering in the Faroe Islands.
Phase III Study of Novaferon in Non-hospitalized Adult Patients With Mild COVID-19 - Condition: Covid19
Interventions: Biological: Novaferon; Biological: Placebo
Sponsors: Genova Inc.; Tokyo Shinagawa Hospital
Recruiting
Human COVID-19 Immunoglobulin (COVID-HIG) Therapy for COVID-19 Patients - Condition: COVID-19
Interventions: Biological: Human COVID-19 immunoglobulin (pH4) for intravenous injection; Drug: Placebo
Sponsors: Sinopharm Wuhan Plasma-derived Biotherapies Co., Ltd.; China National Biotec Group Company Limited; Beijing Tiantan Biological Products Co., Ltd.
Not yet recruiting
A Safety, Tolerability, and Efficacy Study of IBI314 in Mild to Moderate Patients With COVID-19 - Condition: COVID-19
Interventions: Biological: IBI314(low dose); Biological: IBI314(high dose); Biological: IBI314(medium dose); Other: Placebo
Sponsor:
Innovent Biologics (Suzhou) Co. Ltd.
Not yet recruiting
A Study Evaluating Tocilizumab in Pediatric Patients Hospitalized With COVID-19 - Condition: COVID-19
Intervention: Drug: Tocilizumab
Sponsor: Hoffmann- La Roche
Not yet recruiting
Safety, Tolerability, and Treatment Effect of Belnacasan in Patients With COVID-19 - Condition: COVID-19
Interventions: Drug: Belnacasan; Drug: Placebo
Sponsor:
MedStar Health
Recruiting
Safety and Immunogenicity Study of Booster Vaccination in Different Doses of COVID-19 Vaccine (Vero Cell),Inactivated for Prevention of COVID-19 - Condition: COVID-19
Interventions: Biological: High-dosage of COVID-19 vaccine (Vero cell), Inactivated; Biological: Medium-dose COVID-19 Vaccine(Vero Cell),Inactivated
Sponsor:
Sinovac Research and Development Co., Ltd.
Active, not recruiting
Safety and Immunogenicity Study of Booster Vaccination With COVID-19 Vaccine (Vero Cell),Inactivated From Different Manufactures for Prevention of COVID-19 - Condition: COVID-19
Interventions: Biological: Experimental vaccine 1; Biological: Experimental vaccine 2; Biological: Experimental vaccine 3
Sponsor:
Sinovac Research and Development Co., Ltd.
Not yet recruiting
Use of Low-frequency Magnetic Fields in the Hybrid Treatment of COVID-19 Patients - Conditions: COVID-19; COVID-19 Respiratory Infection; COVID-19 Pneumonia
Intervention:
Other: magnetostimulation
Sponsor: Medical University of Lodz
Active, not recruiting
CONFIDENT: Supporting Long-term Care Workers During COVID-19 - Conditions: COVID-19 Pandemic; COVID-19 Vaccine Confidence
Interventions:
Behavioral: Dialogue-Based Webinar; Behavioral: Social Media Website; Other: Enhanced Usual Practice
Sponsors: Dartmouth-Hitchcock Medical Center; National Association of Health Care Assistants; Institute for Healthcare Improvement; East Carolina University
Not yet recruiting
Severity of COVID-19 and Vitamin D Supplementation - Condition: COVID-19 Respiratory Infection
Intervention: Drug: vitamin D
Sponsor: Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health
Active, not recruiting
Quality of Life and Lung Function on Post Covid-19 Patient - Condition: COVID-19
Intervention: Other: breathing exercise, Aerobic exercises
Sponsor: Qassim University
Recruiting
A Study to Evaluate the Ability of UB-612 COVID-19 Vaccine to Boost Immunity of Heterologous COVID-19 Vaccines. - Condition: COVID-19; SARS-CoV-2
Intervention: Biological: UB-612
Sponsor:
United Biomedical Inc., Asia
Not yet recruiting
Multicenter Double Blind, Parallel-group Phase 2/3 Trial, to Study Raloxifene in Adult COVID-19 Patients. - Condition: SARS CoV 2 Infection
Interventions: Drug: Raloxifene; Other: Placebo
Sponsor: Dompé Farmaceutici S.p.A
Completed
Nebulized Fentanyl for Respiratory Symptoms in Patients With COVID-19 - Condition: COVID-19 Pneumonia
Intervention: Drug: Nebulized Fentanyl
Sponsor:
Hamad Medical Corporation
Not yet recruiting
Safety & Immunogenicity of Booster SARS-CoV-2 Vaccine (Vero Cell) - Condition: COVID-19
Intervention: Biological: SARS-COV-2 Vaccine (Vero Cell-Sinopharm) Inactivated
Sponsor: PT. Kimia Farma (Persero) Tbk
Not yet recruiting
Cell-surface glycans act as attachment factors for porcine hemagglutinating encephalomyelitis virus - Porcine hemagglutinating encephalomyelitis virus (PHEV) is a neurotropic coronavirus and highly pathogenic in veterinary clinic. Spike (S) protein of PHEV interplays with host components to cross the plasma membrane of target cells, but characterization of its functional receptors is limited. Here, we discovered that cell-surface glycans, i.e., sialic acid (SA) and heparan sulfate (HS), act as critical interacting factors of PHEV, involving in viral attachment. As shown in glycans depletion…
Structural basis and mode of action for two broadly neutralizing antibodies against SARS-CoV-2 emerging variants of concern - Emerging variants of concern for the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can transmit more efficiently and partially evade protective immune responses, thus necessitating continued refinement of antibody therapies and immunogen design. Here, we elucidate the structural basis and mode of action for two potent SARS-CoV-2 spike (S)-neutralizing monoclonal antibodies, CV3-1 and CV3-25, which remain effective against emerging variants of concern in vitro and in vivo. CV3-1…
In silico bioprospecting of antiviral compounds from marine fungi and mushroom for rapid development of nutraceuticals against SARS-CoV-2 - Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) affects human respiratory function that causes COVID-19 disease. COVID-19 has spread rapidly all over the world and became a pandemic within no time. Therefore, it is the need of hour to screen potential lead candidates from natural resources like edible mushrooms and marine fungi. These natural resources are very less explored till now and known to be the source for many medicinal compounds with several health benefits. These…
The effect of colchicine on mortality outcome and duration of hospital stay in patients with COVID-19: A meta- analysis of randomized trials - BACKGROUND: Overactivation of the NLR family pyrin domain containing 3 (NLRP3) inflammasome can lead to severe illness in patients with coronavirus disease-2019 (COVID-19). The NLRP3 inhibitor, colchicine, therefore, appears to be promising for the treatment of COVID-19.
Review of studies on SARS-CoV-2 infection inhibitors - CONCLUSIONS: The ongoing research is focused on the development of new antiviral agents, as well as the use of the existing drugs on the market. The results of clinical trials are promising and give hope for the development of effective therapies against SARS-CoV-2 and emerging variants of this virus.
S-adenosylmethionine-dependent methyltransferase inhibitor DZNep blocks transcription and translation of SARS-CoV-2 genome with a low tendency to select for drug-resistant viral variants - We report the in vitro antiviral activity of DZNep (3-Deazaneplanocin A; an inhibitor of S-adenosylmethionine-dependent methyltransferase) against SARS-CoV-2, besides demonstrating its protective efficacy against lethal infection of infectious bronchitis virus (IBV, a member of the Coronaviridae family). DZNep treatment resulted in reduced synthesis of SARS-CoV-2 RNA and proteins without affecting other steps of viral life cycle. We demonstrated that deposition of N6-methyl adenosine (m6A) in…
Synthesis and Antiviral Activities of Neoechinulin B and Its Derivatives - We have previously reported that neoechinulin B (1a), a prenylated indole diketopiperazine alkaloid, shows antiviral activities against hepatitis C virus (HCV) via the inactivation of the liver X receptors (LXRs) and the resultant disruption of double-membrane vesicles. In this study, a two-step synthesis of the diketopiperazine scaffold of 1a was achieved by the base-induced coupling of 1,4-diacetyl-3-{[(tert-butyldimethylsilyl)oxy]methyl}piperazine-2,5-dione with aldehydes, followed by the…
Membrane-Based In-Gel Loop-Mediated Isothermal Amplification (mgLAMP) System for SARS-CoV-2 Quantification in Environmental Waters - Since the COVID-19 pandemic is expected to become endemic, quantification of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in ambient waters is critical for environmental surveillance and for early detection of outbreaks. Herein, we report the development of a membrane-based in-gel loop-mediated isothermal amplification (mgLAMP) system that is designed for the rapid point-of-use quantification of SARS-CoV-2 particles in environmental waters. The mgLAMP system integrates the viral…
The polymorphism L412F in TLR3 inhibits autophagy and is a marker of severe COVID-19 in males - The polymorphism L412F in TLR3 has been associated with several infectious diseases. However, the mechanism underlying this association is still unexplored. Here, we show that the L412F polymorphism in TLR3 is a marker of severity in COVID-19. This association increases in the sub-cohort of males. Impaired macroautophagy/autophagy and reduced TNF/TNFα production was demonstrated in HEK293 cells transfected with TLR3^(L412F)-encoding plasmid and stimulated with specific agonist poly(I:C). A…
Human mesenchymal stem cells treatment for severe COVID-19: 1-year follow-up results of a randomized, double-blind, placebo-controlled trial - BACKGROUND: The long-term consequences of human umbilical cord-derived mesenchymal stem cell (UC-MSC) treatment for COVID-19 patients are yet to be reported. This study assessed the 1-year outcomes in patients with severe COVID-19, who were recruited in our previous UC-MSC clinical trial.
Colchicine use in patients with COVID-19: A systematic review and meta-analysis - CONCLUSION: Colchicine may reduce the risk of mortality in individuals with COVID-19. Further prospective investigation may further determine the efficacy of colchicine as treatment in COVID-19 patients in various care settings of the disease, including post-hospitalization and long-term care.
A genome-wide CRISPR screen identifies interactors of the autophagy pathway as conserved coronavirus targets - Over the past 20 years, 3 highly pathogenic human coronaviruses (HCoVs) have emerged-Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV), Middle East Respiratory Syndrome Coronavirus (MERS-CoV), and, most recently, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)-demonstrating that coronaviruses (CoVs) pose a serious threat to human health and highlighting the importance of developing effective therapies against them. Similar to other viruses, CoVs are dependent on host factors…
Computationally prioritized drugs inhibit SARS-CoV-2 infection and syncytia formation - The pharmacological arsenal against the COVID-19 pandemic is largely based on generic anti-inflammatory strategies or poorly scalable solutions. Moreover, as the ongoing vaccination campaign is rolling slower than wished, affordable and effective therapeutics are needed. To this end, there is increasing attention toward computational methods for drug repositioning and de novo drug design. Here, multiple data-driven computational approaches are systematically integrated to perform a virtual…
Investigation of small molecule inhibitors of the SARS-CoV-2 papain-like protease by all-atom microsecond modelling, PELE Monte Carlo simulations, and in vitro activity inhibition - The SARS-CoV-2 papain-like (PL^(pro)) protease is essential for viral replication. We investigated potential antiviral effects of hypericin relative to the well-known noncovalent PL^(pro) inhibitor GRL-0617. Molecular dynamics and PELE Monte Carlo simulations highlight favourable binding of hypericin and GRL-0617 to the naphthalene binding pocket of PL^(pro). Although not potent as GRL-0617 (45.8 vs 1.6µM for protease activity, respectively), in vitro fluorogenic enzymatic assays with hypericin…
Inhibiting TGF-[Formula: see text] 1-Mediated Cellular Processes as an Effective Strategy for the Treatment of Pulmonary Fibrosis with Chinese Herbal Medicines - Pulmonary fibrosis (PF) is a chronic and irreversible interstitial lung disease that even threatens the lives of some patients infected with COVID-19. PF is a multicellular pathological process, including the initial injuries of epithelial cells, recruitment of inflammatory cells, epithelial-mesenchymal transition, activation and differentiation of fibroblasts, etc. TGF-[Formula: see text]1 acts as a key effect factor that participates in these cellular processes of PF. Recently, much attention…
Hung Thanh Phan COVID-19 NEW SOLUTION - - link
METHODS OF TREATING SARS-COV-2 INFECTION - - link
REAL-TIME REST BREAK MANAGEMENT SYSTEM FOR WORKPLACE - The present invention relates to a real-time rest break management system for workplace that comprises of a work desk, wherein first portion is incorporated with a biometric unit 4 for authenticating first user, and a second portion with a telescopic panel 2 associated with a weight sensor 6 and timer unit 7 calculating weight of head/hand manifesting user presence and their resting time period is mounted with an inflated cushion 5, an interactive primary display unit 1 attached over desk enables user to set first/second threshold time for sleeping/taking break, further linked with a tracking interface keeping track of activities and a vibrating unit crafted inside the cushion 5 which is linked to a secondary display unit 8 of second user, giving them access to actuate vibrating unit generating impulses to wake first user when threshold time period is exceeded by the first user. - link
P2P 네트워크를 이용한 내장된 화상회의 시스템 - 본 발명은 P2P 네트워크를 이용한 내장된 화상회의 시스템에 관한 것으로, 상태표시부(1), 영상송출부(2), 제어부(3), 광고부(4), 입력부(5)를 포함한다. - link
小分子化合物肌醇六磷酸酯钠水合物在制备抗SARS-CoV-2药物中的应用 - 本发明公开了小分子化合物肌醇六磷酸酯钠水合物在制备抗严重急性呼吸综合征冠状病毒2(SARS‑CoV‑2)药物中的应用，所述抗SARS‑CoV‑2药物是以肌醇六磷酸酯钠水合物为唯一的活性成份，或包含肌醇六磷酸酯钠水合物的药物组合物，所述抗SARS‑CoV‑2药物是指预防或治疗SARS‑CoV‑2感染的药物。本发明利用SARS‑CoV‑2的易感细胞系，包括非洲绿猴肾细胞Vero
E6以及人肺腺癌细胞Calu‑3，检测肌醇六磷酸酯钠水合物的抗SARS‑CoV‑2活性。实验结果显示，肌醇六磷酸酯钠水合物能有效抑制SARS‑CoV‑2对上述易感细胞的感染，且细胞毒性较小，有希望作为有效抗SARS‑CoV‑2感染的药物，具有应用前景。 - link
A DOORBELL SYSTEM FOR MONITORING AND RECORDING A PHYSIOLOGICAL DATA OF A PERSON - AbstractTitle: A doorbell system for monitoring and recording a physiological data of a person The present invention provides a doorbell system 500 for monitoring and recording a physiological data of a person. The doorbell system 500 having a transmitter module 100 and a receiving module 200. The transmitter module 100 is having a TOF sensor module 110, an ultrasound detector 120, and an infrared detector 130. Further, a speech recognition system 150, a facial recognition system 160, and a temperature detector 190 are provided for recognizing speech, face, and temperature of the person by comparing pre-stored data. A controlling module 180 is set with a predefined commands for communicating with the transmitter module 100 and receiving module 200. The collected facial and speech data is compared and matched with the pre-stored data then the temperature detector 190 triggers and the door opens when the captured body temperature of the person is matched within the predefined range of temperature.Figure 1 - link
Schnelltestsystem, aufweisend: eine Testkassette (11), die ein Testfeld (111) und einen einem bestimmten Benutzer entsprechenden Identifikationsstrichcode (113) aufweist, wobei das Testfeld (111) eine Probe (115) empfängt, um eine Testreaktion (R) zu bewirken, wodurch sich ein der Testreaktion (R) entsprechendes Muster (G) ergibt; und ein tragbares elektronisches Gerät (13), das eine Bildaufnahmeeinheit (131) aufweist, wobei die Bildaufnahmeeinheit (131) das Muster
A study of contemporary trends in investing patterns, household savings, and economic investment. - Because household savings and household investments are intertwined and interdependent, they are discussed briefly in this paper. Household savings account for more than half of a country’s capital formation, which fluctuates due to a variety of economic factors such as inflation and interest rates. Households should gradually shift their savings and investments from physical assets to financial assets to avoid a sudden change in wealth. They should also save and invest using a variety of platforms. Trends in investing and saving will be easier to track and measure this way. This year’s domestic saving rate in India is 2.3 percent lower than last year’s and 1.2 percent lower than the year before. Since 2011, general domestic savings have been steadily declining, with the trend continuing into the following year. According to official data, the GDP in 2020 shrank by 23.9%, the least in previous years and the least since the Covid-19 pandemic in previous years. As a result, the information presented in this paper is drawn from and evaluated from other sources - link
靶向刺激体液免疫和细胞免疫的新冠病毒mRNA疫苗 - 本发明公开了一种靶向刺激体液免疫和细胞免疫的新冠病毒mRNA疫苗。本申请的第一方面提供一种分离的DNA分子组合，该DNA分子组合包括第一DNA分子和第二DNA分子和第三DNA分子中的至少一种。通过第一DNA分子以及第二DNA分子和/或第三DNA分子的组合，利用第一DNA分子最终合成的mRNA诱导高滴度的交叉中和抗体，利用第二DNA分子和/或第三DNA分子最终合成的mRNA诱导新冠病毒特异性的细胞毒性T淋巴细胞，从而高效地同时激活相对独立的体液免疫应答和细胞免疫应答，应对新冠病毒在流行传播过程中产生的突变毒株所引发的突破性感染。 - link
跨膜丝氨酸蛋白酶2抑制剂在制备治疗和/或预防冠状病毒感染药物中的用途 - 本发明公开了跨膜丝氨酸蛋白酶2抑制剂在制备治疗和/或预防冠状病毒感染药物中的用途。本发明通过亲和垂钓及活性导向分离获得3种化合物，证实该类化合物可以直接地与跨膜丝氨酸蛋白酶2结合，KD<13μM，且能够显著抑制跨膜丝氨酸蛋白酶2的催化活性。在细胞水平上可以有效的抑制新型冠状病毒SARS‑CoV‑2假病毒入侵，表明该类化合物对于制备治疗和/或预防病毒感染药物具有非常积极的作用。化合物1 化合物2 化合物3。 - link